• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

7 years ago
News Briefing

BD chief George Golumbes­ki is the lat­est top ex­ec to ex­it Cel­gene dur­ing man­age­ment over­haul

7 years ago
People

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia ...

7 years ago
Pharma

Nabri­va goes 2 for 2 in Phase III an­tibi­ot­ic pro­gram, scor­ing on a key cat­a­lyst -- but shares plunge on safe­ty ...

7 years ago
R&D

Roche adds a stel­lar round of piv­otal da­ta on Hem­li­bra, look­ing to ex­pand its mar­ket for a po­ten­tial mega-block­buster

7 years ago
R&D

An­oth­er cheap, old drug is be­ing fresh­ened up for brand pric­ing in the US — and shares soar, briefly

7 years ago
Bioregnum
R&D

As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic ...

7 years ago
News Briefing

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

7 years ago
R&D

Roivant brings Pfiz­er vets Azoulay, Gul­fo in­to its C-suite; Aileron CEO Joseph Yanchik is out

7 years ago
Peer Review

Syn­dax is hit with a set­back dur­ing the AS­CO pre­view round as lead drug flops in mid-stage study

7 years ago
R&D

J&J ax­es its big BACE pro­gram in asymp­to­matic Alzheimer's pa­tients as the drum­beat of PhI­II fail­ures rolls on

7 years ago
R&D

Al­ler­gan faces fresh woes with Resta­sis patents as Wal­green, re­tail­ers file law­suit over 'an­ti­com­pet­i­tive con­duc­t'

7 years ago
Pharma

For­get RNA drugs. Ac­cent gets $40M to de­vel­op small mol­e­cules that mod­i­fy RNA in­stead

7 years ago
Financing
Startups

Am­gen, No­var­tis ready to roll as FDA green lights block­buster cam­paign for mi­graine drug — priced at $6,900

7 years ago
Pharma

Who’s de­lay­ing gener­ic com­pe­ti­tion? FDA pub­lish­es a long list of drug­mak­ers they say gamed the sys­tem

7 years ago
Pharma

Why would Co­hen reach out to No­var­tis, but not Roche?; WuXi Bi­o­log­ics blue­prints big R&D/man­u­fac­tur­ing com­plex

7 years ago
News Briefing

FDA faults IQVIA for er­rors in opi­oid sales da­ta, calls for qual­i­ty re­view

7 years ago
Pharma

FDA ap­proves first non-opi­oid to treat with­draw­al symp­toms in adults

7 years ago
Pharma

Will Shire's top R&D tal­ent bolt now that Take­da has struck a merg­er agree­ment?

7 years ago
Deals
R&D

FDA ex­e­cutes an abrupt about-face as sole-source con­tract for ex-agency chief Mark Mc­Clel­lan draws the spot­light

7 years ago
Pharma

Cit­ing sig­nif­i­cant progress on a cure for di­a­betes, No­vo Nordisk beefs up its stem cell pipeline with new ...

7 years ago
R&D

The top win­ners and losers on AS­CO ab­stract night: Loxo, Blue­print, Jounce, Mer­ck KGaA and more

7 years ago
R&D

Vec­talys and Flash­Cell merge in­to Flash Ther­a­peu­tics, loaded with RNA pipeline and man­u­fac­tur­ing set-up

7 years ago
Deals

As­traZeneca steps up its use of Em­u­late's 'or­gan chip' tech; An­sun Bio­phar­ma's parain­fluen­za ther­a­py at­tracts $85M ...

7 years ago
News Briefing
First page Previous page 1026102710281029103010311032 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.